Methylphenidate extended release - Highland Therapeutics
Alternative Names: Benjorna; HLD-200; JORNAY PM; Methylphenidate delayed release; Methylphenidate hydrochloride extended releaseLatest Information Update: 09 Oct 2024
At a glance
- Originator Highland Therapeutics
- Developer Collegium Pharmaceutical; Highland Therapeutics; Ironshore Pharmaceuticals (America) Inc
- Class Behavioural disorder therapies; Neuroprotectants; Nootropics; Phenylacetates; Piperidines; Sleep disorder therapies; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Central nervous system stimulants; Dopamine uptake inhibitors; Monoamine oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Attention-deficit hyperactivity disorder
Most Recent Events
- 13 Sep 2024 Phase-III clinical trials in Attention-deficit hyperactivity disorder (In children) in USA (PO) (NCT06431256)
- 04 Sep 2024 Ironshore Pharmaceutical and Development has been acquired and merged into Collegium Pharmaceutical
- 31 May 2024 Ironshore Pharmaceuticals and Development plans a phase III trial for Attention deficit hyperactivity disorder (PO, Capsules) in August 2024 (NCT06431256)